{
  "docId": "019de073-a59c-77cf-8e75-229e6c5c9530",
  "docSlug": "74412512a1adb89488775a4a2b6a1b7b",
  "documentTitle": "Avenue Therapeutics | IPO Presentation Deck | 30 slides",
  "authorId": "avenue-therapeutics",
  "authorName": "Avenue Therapeutics",
  "documentKindSlug": "regulatory-filing",
  "documentKindLabel": "Regulatory filing",
  "sourceTypeSlug": "investment_bank",
  "sourceTypeLabel": "Investment bank",
  "presentationDate": "2022-10-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7761332,
  "pageNumber": 20,
  "pageCount": 30,
  "prevPage": 19,
  "nextPage": 21,
  "slideType": "competitive_analysis",
  "function": "compare_peers",
  "density": "dense",
  "nDataPoints": 20,
  "notes": "The slide uses a comparison table to frame BAER-101's selectivity profile as a competitive advantage.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-a59c-77cf-8e75-229e6c5c9530/20",
  "deckHref": "/decks/019de073-a59c-77cf-8e75-229e6c5c9530",
  "deckJsonHref": "/decks/019de073-a59c-77cf-8e75-229e6c5c9530.json",
  "deckAnchorHref": "/decks/019de073-a59c-77cf-8e75-229e6c5c9530#slide-20",
  "components": [
    {
      "bbox": {
        "h": 0.15,
        "w": 0.9,
        "x": 0.05,
        "y": 0.62
      },
      "kind": "list",
      "text": "BAER-101 is selective to the a2/3 receptor subunits and BAER-101 does not have high activity with the a5 subunit. Furthest along GABAa compound in clinical development is darigabat from Cerevel, which targets the a5 subunit in addition to the a2/3 receptor subunits.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "40039bd1-92dc-4063-a616-95aee77bb2bd",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.87,
        "x": 0.08,
        "y": 0.78
      },
      "kind": "list",
      "text": "Targeting the a5 receptor subunit is associated with tolerance development and this is potentially detrimental to developing a clinically effective drug for chronic use as resistance to the drug can occur over time. In addition, the a5 receptor subunit is also associated with sedation. BAER-101, unlike darigabat, is less likely to lead to treatment resistance and sedation.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "545f31a2-8f2b-40d8-be38-0b76aa15061e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.9,
        "x": 0.05,
        "y": 0.21
      },
      "kind": "table",
      "text": "BAER-101 differentiation vs competitions",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d1a19fc8-3944-4232-a776-9ce62aae5d25",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.55,
        "x": 0.05,
        "y": 0.11
      },
      "kind": "title",
      "text": "BAER-101 is differentiated from others in the class",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "72426462-0ef8-45f7-b0ab-1c93a4142cc8",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "comparison_frame",
      "slug": null,
      "matchId": "2acfbd43-92c7-41fa-bce8-31e8e08a1a42",
      "evidence": "The slide uses a table to compare BAER-101 against competitors based on selectivity and clinical phase.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}